ChartMill assigns a Buy % Consensus number of 86% to IBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | Oppenheimer | Initiate | Outperform |
| 2025-10-17 | Leerink Partners | Initiate | Outperform |
| 2025-06-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2024-07-22 | Brookline Capital | Initiate | Buy |
| 2024-06-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-28 | Chardan Capital | Initiate | Buy |
| 2023-02-16 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2022-10-07 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2021-11-29 | JMP Securities | Initiate | Outperform |
10 analysts have analysed IBIO and the average price target is 4.49 USD. This implies a price increase of 66.22% is expected in the next year compared to the current price of 2.7.
The consensus rating for IBIO INC (IBIO) is 86 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering IBIO INC (IBIO) is 10.